Cantacuzino Institute will most probably produce anti-flu vaccine again as of next year, after a new series of micro production tests will be run during 2016, the institute’s manager Adrian Ionel told Agerpres.
According to him, the institute’s experts will also test a new distillation method that would cut out a lot of impurities and thus, they expect the best vaccine version. “We are almost sure that we’ll have a Romanian anti-flu vaccine production with the proper qualities as of next year,” Ionel said.
He also informed more experts would be hired at the Institute this month, in an attempt to bring again the employeess who left the institute in the past due to some inside conflicts. Moreover, he said there is an agreement with Pasteur Institute to send some of their experts in Romania this month to train the staff of the Cantacuzino Institute.
Cantacuzino National Institute of Research-Development for Microbiology and Immunology (CNIR) is a national institute in Romania, which does scientific research in the fields of microbiology, immunology, molecular biology and genetics, and education of microbiology, immunology, epidemiology, training of scientific and technical. Despite ranking among the most appreciated immunological producers in the world, the institute has started to face decline since February 2010, after the National Agency of Medicines withdrew its authorization to sell products for injection, including vaccines, as the fabrication standard had expired. Under these conditions, some immunization national programs have been blocked for several months, while the authorities being compelled to import other vaccines.
Media and civil society have long blamed the state authorities of closing their eyes or even of being hand in hand with the foreign drug companies that would want their medicine and vaccines prevail on the Romanian market.
Last autumn the government informed it was waiting for the EC green light to grant a state aid to Cantacuzino institute to write off all its debts.